Sean F Moran's most recent trade in Corbus Pharmaceuticals Holdings Inc was a trade of 2,792 Common Stock, par value $0.0001 per share done at an average price of $8.8 . Disclosure was reported to the exchange on Feb. 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.76 per share. | 14 Feb 2025 | 2,792 | 73,313 (0%) | 0% | 8.8 | 24,446 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 92,500 | 92,500 | - | - | Stock options (right to buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 27,500 | 76,105 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 7,788 | 23,367 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.87 per share. | 14 Jun 2024 | 7,788 | 48,605 (0%) | 0% | 49.9 | 388,417 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 7,788 | 56,393 (0%) | 0% | 4.3 | 33,177 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 6,730 | 11,217 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.77 per share. | 14 Jun 2024 | 6,730 | 48,605 (0%) | 0% | 46.8 | 314,789 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.10 per share. | 14 Jun 2024 | 6,730 | 55,335 (0%) | 0% | 14.1 | 94,893 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,958 | 0 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.12 per share. | 14 Jun 2024 | 1,958 | 48,605 (0%) | 0% | 42.1 | 82,479 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 1,958 | 50,563 (0%) | 0% | 30 | 58,740 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 1,567 | 50,172 (0%) | 0% | 30 | 47,010 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,567 | 1,958 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.87 per share. | 14 Jun 2024 | 1,567 | 48,605 (0%) | 0% | 49.9 | 78,152 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 1,787 | 0 | - | - | Employee Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 10 Apr 2024 | 1,787 | 48,605 (0%) | 0% | 30 | 53,610 | Common Stock |
| Corbus Pharmaceuticals | Moran F. Sean | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 40,176 | 46,818 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 40,176 | 40,176 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 934,645 | 934,645 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.26 per share. | 10 Aug 2022 | 20,000 | 199,272 (0%) | 0% | 0.3 | 5,198 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.30 per share. | 16 May 2022 | 12,000 | 179,272 (0%) | 0% | 0.3 | 3,600 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 10 Mar 2022 | 15,000 | 167,272 (0%) | 0% | 0.4 | 5,550 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 538,400 | 538,400 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 307,300 | 307,300 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 87,500 | 87,500 | - | - | Stock Option (Right to Buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 18 Dec 2020 | 87,500 | 349,610 (0%) | 0% | 1.8 | 153,125 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.40 per share. | 18 Dec 2020 | 87,500 | 437,110 (0%) | 0% | 1.4 | 122,500 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.00 per share. | 18 Dec 2020 | 53,610 | 403,220 (0%) | 0% | 1 | 53,610 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 53,610 | 53,610 | - | - | Stock Option (Right to Buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 18 Dec 2020 | 53,610 | 349,610 (0%) | 0% | 1.4 | 75,054 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.17 per share. | 16 Dec 2020 | 36,923 | 386,533 (0%) | 0% | 0.2 | 6,118 | Common Stock |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 36,923 | 36,923 | - | - | Stock Option (Right to Buy) | |
| Corbus Pharmaceuticals | Sean F. Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.32 per share. | 16 Dec 2020 | 36,923 | 349,610 (0%) | 0% | 1.3 | 48,628 | Common Stock |